NCT03142165View on ClinicalTrials.gov

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 11, 2017

Primary Completion Date

November 29, 2017

Study Completion Date

November 29, 2017

Conditions
Fibrosis
Interventions
DRUG

BMS-986263

3 weekly doses of 90 mg infused intravenous administration

OTHER

Placebo

Placebo

DRUG

Diphenhydramine

50 mg intravenous administration

DRUG

Famotidine

20 mg intravenous administration

Trial Locations (1)

90630

Wcct Global, Llc, Cypress

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03142165 - A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants | Biotech Hunter | Biotech Hunter